| Literature DB >> 27242899 |
Rosita A Condorelli1, Enzo Vicari1, Laura M Mongioi1, Giorgio I Russo2, Giuseppe Morgia2, Sandro La Vignera1, Aldo E Calogero1.
Abstract
This study evaluated the ultrasound (US) features of 20 patients with MAGI and concomitant papilloma virus (HPV) infection compared to 20 patients with microbial (presence of Chlamydia trachomatis alone) MAGI and 20 patients with amicrobial (inflammatory) MAGI. Patients with HPV infection showed significantly (p < 0.05) higher total prostate, seminal vesicles, and epididymal US signs (18.0 ± 2.0) compared to the other 2 groups (12.0 ± 4.0 versus 10.0 ± 3.0, resp.). In addition, patients with MAGI and HPV had a higher prevalence of complicated forms of MAGI [prostatovesiculitis (PV) and prostate-vesiculo-epididymitis (PVE)] and a higher frequency of the fibrosclerotic variant compared to the other groups (70.0 ± 10.0% versus 48.0 ± 5.0% versus 15.0 ± 10.0%). Moreover, HPV infected patients had a higher number of US criteria suggestive for MAGI in the periurethral region of the prostate compared to the other groups. In particular, the patients showed a higher ratio between periurethral and lobar US criteria distribution (5.0 versus 0.5). Finally, the seminal fluid concentration of CD45pos leukocytes (2.0 ± 0.2 versus 1.3 ± 0.3 versus 1.0 ± 0.3 mil/mL) was significantly higher and sperm progressive motility was significantly lower in these patients compared to other groups.Entities:
Year: 2016 PMID: 27242899 PMCID: PMC4868901 DOI: 10.1155/2016/9174609
Source DB: PubMed Journal: Int J Endocrinol ISSN: 1687-8337 Impact factor: 3.257
Figure 1Examples of ultrasonographic suggestive images in patients with MAGI. (a) US subdivision of the prostate in periurethral and lobar regions. (b) Chronic vesiculitis. (c) Chronic epididymitis.
Anthropometric measurements and clinical symptom scores in the three groups of patients with male accessory gland infection/inflammation (MAGI) enrolled in this study.
| Parameters | MAGI | MAGI | Inflammatory MAGI |
|---|---|---|---|
| Anthropometric parameters | |||
| Age (years) | 26.0 ± 4.0 | 26.0 ± 8.0 | 28.0 ± 6.0 |
| BMI (kg/m2) | 21.0 ± 4.0 | 20.0 ± 3.0 | 22.0 ± 4.0 |
|
| |||
| Clinical symptoms/signs | |||
| Urinary tract symptoms | 8.0 ± 4.0 | 6.0 ± 3.0 | 6.0 ± 2.0 |
| Spontaneous and/or ejaculatory pain or discomfort | 14.0 ± 4.0 | 13.0 ± 4.0 | 11.0 ± 3.0 |
| Sexual dysfunction | 15.0 ± 4.0 | 14.0 ± 3.0 | 12.0 ± 6.0 |
| Impact on the quality-of-life | 12.0 ± 4.0 | 12.0 ± 2.0 | 10.0 ± 2.0 |
Urinary tract symptoms severity score: mild: 0–6; moderate: 7–12; severe: 13–18.
Spontaneous and/or ejaculatory pain or discomfort severity score: mild: 0–8; moderate: 9–16; severe: 17–24.
Sexual dysfunction severity score: mild: 0–11; moderate: 12–22; severe: 23–33.
Impact on the quality-of-life severity score: mild: 0–5; moderate: 6–10; severe: 11–15.
Sperm parameters and seminal fluid leucocyte concentration measured by flow cytometry in the three groups of patients with male accessory gland infection/inflammation (MAGI) enrolled in this study.
| Parameters | MAGI | MAGI | Inflammatory MAGI |
|---|---|---|---|
| Seminal fluid volume (mL) | 1.5 ± 0.5 | 1.8 ± 0.8 | 1.6 ± 0.8 |
| Sperm concentration (million/mL) | 11.0 ± 4.0 | 12.0 ± 4.0 | 14.0 ± 6.0 |
| Progressive motility (%) | 8.0 ± 3.0 | 13.0 ± 5.0 | 15.0 ± 8.0 |
| Normal forms (%) | 4.0 ± 1.0 | 4.0 ± 2.0 | 5.0 ± 2.0 |
| Peroxidase-positive leukocytes (million/mL) | 2.4 ± 0.5 | 2.3 ± 0.8 | 2.0 ± 0.6 |
| CD45pos leukocytes (million/mL) | 2.0 ± 0.2 | 1.3 ± 0.3 | 1.0 ± 0.3 |
| CD45+CD16+ (%) | 23.0 ± 7.0 | 55.0 ± 12.0 | 50.0 ± 6.0 |
HPV: human papilloma virus. p < 0.05 versus patients with MAGI Chlamydia trachomatis-positive; † p < 0.05 versus patients with inflammatory MAGI.
Ultrasound features in the three groups of patients with male accessory gland infection/inflammation (MAGI) enrolled in this study.
| Parameters | MAGI | MAGI | Inflammatory MAGI |
|---|---|---|---|
| Ultrasound (US) features | |||
| Total number of US criteria suggestive for MAGI | 18.0 ± 2.0 | 12.0 ± 4.0 | 10.0 ± 3.0 |
| Total number of US criteria in the prostate periurethral zone | 5.0 ± 1.0 | 2.0 ± 1.0 | 2.0 ± 1.0 |
| Total number of US criteria in the prostate lobar zone | 1.0 ± 1.0 | 4.0 ± 1.0 | 4.0 ± 1.0 |
|
| |||
| Prevalence of the various diagnostic categories of MAGI | |||
| Prostatitis (%) | 18.0 ± 6.0† | 27.0 ± 5.0† | 65.0 ± 10.0 |
| Prostate-vesiculitis (%) | 40.0 ± 10.0† | 45.0 ± 5.0† | 20.0 ± 5.0 |
| Prostate-vesiculitis-epididymitis (%) | 42.0 ± 4.0 | 28.0 ± 5.0† | 15.0 ± 5.0 |
|
| |||
| Prevalence of monolateral versus bilateral forms of MAGI | |||
| Monolateral prostatitis (%) | 10.0 ± 3.0 | 17.0 ± 5.0† | 45.0 ± 5.0 |
| Monolateral prostate-vesiculitis (%) | 10.0 ± 5.0 | 15.0 ± 5.0 | 15.0 ± 5.0 |
| Monolateral prostate-vesiculitis-epididymitis (%) | 12.0 ± 5.0 | 10.0 ± 5.0 | 10.0 ± 5.0 |
| Bilateral prostatitis (%) | 8.0 ± 3.0† | 10.0 ± 5.0† | 20.0 ± 5.0 |
| Bilateral prostate-vesiculitis (%) | 30.0 ± 5.0† | 30.0 ± 5.0† | 5.0 ± 5.0 |
| Bilateral prostate-vesiculitis-epididymitis (%) | 30.0 ± 5.0 | 18.0 ± 5.0† | 5.0 ± 5.0 |
|
| |||
| Prevalence of fibrosclerotic versus hypertrophic-congestive variant of MAGI | |||
| Fibrosclerotic MAGI (%) | 70.0 ± 10.0 | 48.0 ± 5.0† | 15.0 ± 10.0 |
| Hypertrophic-congestive MAGI (%) | 30.0 ± 10.0 | 52.0 ± 5.0† | 85.0 ± 10.0 |
HPV: human papilloma virus. p < 0.05 versus patients with MAGI Chlamydia trachomatis-positive; † p < 0.05 versus patients with inflammatory MAGI.
Additional criteria for the clinical management of patients with male accessory gland infection/inflammation (MAGI).
| What to do? | When? |
|---|---|
|
| (i) All patients with MAGI |
| (ii) Bilateral prostate-vesicular-epididymitis | |
| (iii) Fibrosclerotic variant of MAGI | |
| (iv) Periurethral prostate sign | |
|
| |
| Ultrasound evaluation | (i) To define the diagnostic category of MAGI (prostatitis alone and prostate-vesiculitis versus prostate-vesicular-epididymitis) |
| (ii) To determine if MAGI is monolateral or bilateral | |
| (iii) For a prognostic evaluation (before treatment) | |
| (iv) To evaluate the persistence (after treatment) | |
| (v) To evaluate the eradication (after treatment) | |
| (vi) For a differential diagnosis (viral versus other forms) | |
|
| |
| Seminal fluid leukocyte measurement by CD45 antibody staining (relatively expensive, nonroutine investigation). | (i) To evaluate the persistence (after treatment) |
| (ii) To evaluate the eradication (after treatment) | |
| (iii) Viral etiology ( | |